Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Color Diagnostics, |
RCV001191322 | SCV001359097 | uncertain significance | Cardiomyopathy | 2019-07-20 | criteria provided, single submitter | clinical testing | This variant is located in intron 44 of the RYR2 gene. Computational splicing tools and conservation analyses are inconclusive regarding the impact of this variant on RNA splicing. To our knowledge, functional assays have not been performed for this variant nor has this variant been reported in individuals affected with cardiovascular disorders in the literature. This variant has been identified in 5/280480 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003317104 | SCV004020765 | uncertain significance | not specified | 2023-06-18 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003372624 | SCV004094502 | uncertain significance | Cardiovascular phenotype | 2023-06-28 | criteria provided, single submitter | clinical testing | The c.6793-4G>T intronic variant results from a G to T substitution 4 nucleotides upstream from coding exon 45 in the RYR2 gene. This nucleotide position is not well conserved in available vertebrate species. In silico splice site analysis for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Blueprint Genetics | RCV000157459 | SCV000207203 | uncertain significance | Primary familial hypertrophic cardiomyopathy | 2014-04-17 | no assertion criteria provided | clinical testing |